vVARDIS' Drill-Free Solution Curodont ™ Has Treated Over One Million Teeth in 18 Months and Is the Fastest Growing Dental Care Product in Its Category

Business Wire

24-07-2025

ZUG, Switzerland--(BUSINESS WIRE)-- vVARDIS, a Swiss high-growth healthcare company, active in the development of innovative dental products, today announced that more than one million teeth and more than 420,000 patients have been treated in the United States since January 2024 with Curodont™, its drill-free solution for early stage tooth decay, making it the fastest growing dental care product in its category i ii.
Nearly 80 percent of all dental patients have early tooth decay iii. Oral health is an important aspect of overall health, and poor oral health, including untreated decay, can become life-threatening. With Curodont™, dental teams have a drill-free solution to treat tooth decay at an early stage.
Curodont™ represents a true win-win proposition: patients benefit from a quick, needle- and drill-free treatment, while dental professionals can treat early decay within minutes—eliminating the need for a follow-up appointment and freeing up chair time for more complex procedures.
'Now that Curodont™ is available in nearly 10 percent of U.S. dental offices iv, an increasing number of dental professionals – or 'Curodontists' – are embracing our treatment and giving patients access to this revolutionary solution,' said Dr. Haley Abivardi, DMD, co-CE, and co-founder of vVARDIS. 'Such high-speed adoption shows how dental professionals have been waiting for decades for a solution that enables them to treat tooth decay at an early stage.'
Dr. Goly Abivardi, DMD, co-CEO and co-founder of vVARDIS, said, 'We are thrilled to witness a ground-breaking transformation in dentistry similar to the advancements that medicine embraced years ago toward non-invasive, early intervention approaches. In the same way, Curodont™ is helping to elevate the standard of care for the early treatment of cavities.'
With more than 25 years of science, vVARDIS' Curodont™ is backed by universities internationally and has earned the endorsement of renowned thought leaders, clinical experts, and innovators across the dental profession:
Dr. German O. Gallucci, Chair of the Department of Restorative Dentistry and Biomaterials Sciences at Harvard School of Dental Medicine, said, 'Curodont™ is highly effective for treatment of early decays. This new non-invasive therapeutic option is a game changer in the battle against tooth decay.'
Prof. Amid I. Ismail, Laura H. Carnell Professor and Dean of the Kornberg School of Dentistry, Temple University, said, 'As an epidemiologist and cariologist who has studied dental caries for over four decades and developed guidelines for its diagnosis and management, I can state without hesitation that the advent of Curodont™ represents a significant breakthrough in caries management.'
Dr. Timothy Quirt, DDS, MBA, Senior Vice President, Clinical Operations at Heartland Dental, said, 'Curodont™ represents a transformative step forward in dentistry. At Heartland Dental, we've seen firsthand how this innovation empowers clinicians to treat early-stage caries non-invasively, improving outcomes and deepening patient trust. It's not just a product – it's a shift in how we think about the future of oral health.'
Dr. Shan K. Bagby, DMD, MHA, FACHE, Brigadier General, USA (Ret.) has recognized Curodont's™ potential to improve the health of children from lower-income homes, saying, 'What makes Curodont™ especially impactful is its potential to reduce tooth decay among vulnerable populations—particularly children and those covered by Medicaid. Curodont™ isn't just a new tool; it's a meaningful, science-driven advancement that is reshaping healthcare and setting a higher standard for dentistry where it's needed most." v
Prof. Avijit Banerjee, Professor of Cariology & Operative Dentistry; Hon Consultant in Restorative Dentistry, Faculty of Dentistry, Oral & Craniofacial Sciences, King's College London, said, 'The scientific research into Curodont™ Repair technology has been well documented in reputable scientific peer-reviewed journals since the late 1990s. Multiple published clinical studies, including systematic meta-analyses, have provided evidence that, unlike conventional topical re-mineralizing agents which primarily act on the surface of the tooth, Curodont™ Repair can treat early decay throughout the depth of the lesion.' vi
Prof. Ivo Krejci, University of Geneva, said: 'Curodont™ is no longer the future. It's the present and it should be part of the treatment spectrum in every modern dental practice.'
vVARDIS's Curodont™ products are currently available in the U.S. and Europe and will continue to roll out globally.
About Curodont™
Using a proprietary biomimetic formulation, Curodont™ is a groundbreaking clinically proven drill-free treatment for early tooth decay. It replicates and builds on the body's natural defenses, working together with minerals in the saliva to repair the damage done to the tooth in the early stages of tooth decay. Curodont™ is a non-invasive, drill-free solution: once the formula is applied, it diffuses through the enamel and repairs the missing parts of the tooth (lesions) with minerals from saliva by mimicking the way nature created teeth (biomimetic). The beauty of this product is that Curodont™ helps patients save the natural tooth structure without artificial filling materials.
About vVARDIS AG
vVARDIS is a Swiss high-growth healthcare company located in Zug, Switzerland that offers groundbreaking biomimetic, non-invasive solutions for dental professionals under the Curodont™ brand. Founded by Drs. Haley and Goly Abivardi, sisters, Swiss dentists, innovators, and awarded entrepreneurs, vVARDIS is the result of more than 25 years of research, paired with the commitment of its founders to make an impact on people's lives, especially the underserved.
vVARDIS' mission is to expand access to novel approaches to the standard of care in dentistry with the purpose of improving oral health – the foundation for overall health. vVARDIS is backed by more than 25 years of science, 230 scientific publications, including meta-analysis, peer-reviewed clinical studies and a long-term peer-reviewed real-world evidence study demonstrating a success rate above 90 percent. It has been used in clinical practice for more than 10 years. Curodont™ is already mentioned in lectures at renowned universities as a standard of care for the treatment of early decay.
www.vVARDIS.com and www.linkedin.com/company/vvardis.